The Centers for Medicare and Medicaid Services announced that it would only cover the expensive new Alzheimer’s treatment from Biogen for patients enrolled in clinical trials, significantly limiting the patient population that could benefit from it.

“CMS has proposed an evidence-based coverage policy after experts reviewed all relevant publicly available evidence and feedback received from stakeholders,” said CMS Administrator Chiquita Brooks-LaSure.

Recommended Stories

No, Abdul el Sayed, the Second Amendment doesn’t mean muskets only

GOP lawmaker calls for FCC inquiry into outlets that reported on fabricated Wedgewood polling

Will Serbia elections break Vucic’s grip on power?